138 related articles for article (PubMed ID: 10067701)
21. Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract.
Simecka JW; Jackson RJ; Kiyono H; McGhee JR
Infect Immun; 2000 Feb; 68(2):672-9. PubMed ID: 10639432
[TBL] [Abstract][Full Text] [Related]
22. Oral vaccine models: multiple delivery systems employing tetanus toxoid.
Jackson RJ; Staats HF; Xu-Amano J; Takahashi I; Kiyono H; Hudson ME; Gilley RM; Chatfield SN; McGhee JR
Ann N Y Acad Sci; 1994 Aug; 730():217-34. PubMed ID: 8080173
[TBL] [Abstract][Full Text] [Related]
23. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
24. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
[TBL] [Abstract][Full Text] [Related]
25. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.
Tochikubo K; Isaka M; Yasuda Y; Kozuka S; Matano K; Miura Y; Taniguchi T
Vaccine; 1998; 16(2-3):150-5. PubMed ID: 9607023
[TBL] [Abstract][Full Text] [Related]
26. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid.
Gupta RK; Siber GR
Biologicals; 1994 Mar; 22(1):53-63. PubMed ID: 8068314
[TBL] [Abstract][Full Text] [Related]
27. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.
Wu HY; Russell MW
Vaccine; 1998; 16(2-3):286-92. PubMed ID: 9607044
[TBL] [Abstract][Full Text] [Related]
28. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
Goto N; Maeyama J; Yasuda Y; Isaka M; Matano K; Kozuka S; Taniguchi T; Miura Y; Ohkuma K; Tochikubo K
Vaccine; 2000 Apr; 18(20):2164-71. PubMed ID: 10715532
[TBL] [Abstract][Full Text] [Related]
29. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
Westerink MA; Smithson SL; Srivastava N; Blonder J; Coeshott C; Rosenthal GJ
Vaccine; 2001 Dec; 20(5-6):711-23. PubMed ID: 11738734
[TBL] [Abstract][Full Text] [Related]
30. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
Price GA; Russell MW; Cornelissen CN
Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
[TBL] [Abstract][Full Text] [Related]
31. Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep.
Chen D; Colditz IG; Glenn GM; Tsonis CG
Vet Immunol Immunopathol; 2002 Jul; 86(3-4):177-82. PubMed ID: 12007883
[TBL] [Abstract][Full Text] [Related]
32. Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone.
Samore MH; Siber GR
Vaccine; 1996 Mar; 14(4):290-7. PubMed ID: 8744555
[TBL] [Abstract][Full Text] [Related]
33. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
Maeyama J; Isaka M; Yasuda Y; Matano K; Kozuka S; Taniguchi T; Ohkuma K; Tochikubo K; Goto N
Microbiol Immunol; 2001; 45(2):111-7. PubMed ID: 11293476
[TBL] [Abstract][Full Text] [Related]
34. Development of an animal model to assess the immunogenicity of single-dose tetanus and diphtheria vaccines based on controlled release from biodegradable polymer microspheres.
Gupta RK; Griffin P; Rivera R; Siber GR
Dev Biol Stand; 1998; 92():277-87. PubMed ID: 9554282
[TBL] [Abstract][Full Text] [Related]
35. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract.
Gockel CM; Bao S; Beagley KW
Mol Immunol; 2000 Jun; 37(9):537-44. PubMed ID: 11163403
[TBL] [Abstract][Full Text] [Related]
36. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
[TBL] [Abstract][Full Text] [Related]
37. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.
Marinaro M; Staats HF; Hiroi T; Jackson RJ; Coste M; Boyaka PN; Okahashi N; Yamamoto M; Kiyono H; Bluethmann H; Fujihashi K; McGhee JR
J Immunol; 1995 Nov; 155(10):4621-9. PubMed ID: 7594461
[TBL] [Abstract][Full Text] [Related]
38. Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets.
Amuguni H; Lee S; Kerstein K; Brown D; Belitsky B; Herrmann J; Keusch G; Sonenshein A; Tzipori S
Microbes Infect; 2012 May; 14(5):447-56. PubMed ID: 22198093
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin E-suppressing and immunoglobulin G-enhancing tetanus toxoid prepared by conjugation with pullulan.
Mitani S; Yamamoto A; Ikegami H; Usui M; Matuhasi T
Infect Immun; 1982 Jun; 36(3):971-6. PubMed ID: 7095857
[TBL] [Abstract][Full Text] [Related]
40. Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses.
Marinaro M; Fasano A; De Magistris MT
Infect Immun; 2003 Apr; 71(4):1897-902. PubMed ID: 12654806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
